The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC
Concurrent chemotherapy and radiation therapy remains the standard-of-care treatment in patients with unresectable stage III non-small-cell lung cancer. Most regimens include low doses of radiosensitizing agents. Because of concern for the presence of micrometastatic disease and the high rate of sys...
Gespeichert in:
| Veröffentlicht in: | Current oncology reports 2013-08, Vol.15 (4), p.424-432 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 432 |
|---|---|
| container_issue | 4 |
| container_start_page | 424 |
| container_title | Current oncology reports |
| container_volume | 15 |
| creator | Fakhrejahani, Farhad Hashemi Sadraei, Nooshin Mekhail, Tarek |
| description | Concurrent chemotherapy and radiation therapy remains the standard-of-care treatment in patients with unresectable stage III non-small-cell lung cancer. Most regimens include low doses of radiosensitizing agents. Because of concern for the presence of micrometastatic disease and the high rate of systemic failure, many trials have addressed the role of additional consolidation chemotherapy. Only a few of these studies have been performed in a randomized setting on a large number of patients, and the rest are smaller phase I and phase II trials that explore the safety and efficacy of different chemotherapy regimens. More recently, targeted agents have also been evaluated in such regimens, although molecular and histologic markers have not been fully incorporated in these studies. In this review, we discuss these trials and compare the different sequences and regimens of systemic doses of chemotherapy when delivered in addition to concurrent chemotherapy and radiation therapy. |
| doi_str_mv | 10.1007/s11912-013-0330-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1411631562</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3647107041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-b8ecf71f3cba99c2c417e11ba3f6e896f5824b65f146906c2bbfd373c9736423</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMorl8_wIsUvHipZpJukh6l-MmioOs5pOlEK91Ek67gv7dlVxHBUwbyvO8MDyGHQE-BUnmWAEpgOQWeU85prjbIDkx5kQsmys1xZjznsqQTspvSK6WMUkW3yYRxqahibIfczl8wewgdZsFlVfApdG1j-jb4bB7R9Av0fdb6bBas6brP7Lz5MN5ikz35iAltb-ohe_dYzap9suVMl_Bg_e6R-eXFvLrOZ_dXN9X5LLdcsj6vFVonwXFbm7K0zBYgEaA23AlUpXBTxYpaTB0UoqTCsrp2DZfclpKLgvE9crKqfYvhfYmp14s2Wew64zEsk4YCQHCYihE9_oO-hmX0w3EahKRMAUg1ULCibAwpRXT6LbYLEz81UD161ivPevCsR896zBytm5f1ApufxLfYAWArIA1f_hnjr9X_tn4B5OmF8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1670281178</pqid></control><display><type>article</type><title>The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Fakhrejahani, Farhad ; Hashemi Sadraei, Nooshin ; Mekhail, Tarek</creator><creatorcontrib>Fakhrejahani, Farhad ; Hashemi Sadraei, Nooshin ; Mekhail, Tarek</creatorcontrib><description>Concurrent chemotherapy and radiation therapy remains the standard-of-care treatment in patients with unresectable stage III non-small-cell lung cancer. Most regimens include low doses of radiosensitizing agents. Because of concern for the presence of micrometastatic disease and the high rate of systemic failure, many trials have addressed the role of additional consolidation chemotherapy. Only a few of these studies have been performed in a randomized setting on a large number of patients, and the rest are smaller phase I and phase II trials that explore the safety and efficacy of different chemotherapy regimens. More recently, targeted agents have also been evaluated in such regimens, although molecular and histologic markers have not been fully incorporated in these studies. In this review, we discuss these trials and compare the different sequences and regimens of systemic doses of chemotherapy when delivered in addition to concurrent chemotherapy and radiation therapy.</description><identifier>ISSN: 1523-3790</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-013-0330-8</identifier><identifier>PMID: 23780822</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Antineoplastic Agents - therapeutic use ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Clinical Trials as Topic ; Consolidation Chemotherapy - methods ; Drug Substitution ; Humans ; Lung Cancer (T Mekhail ; Lung Neoplasms - drug therapy ; Medicine ; Medicine & Public Health ; Neoplasm, Residual - drug therapy ; Oncology ; Radiation-Sensitizing Agents - therapeutic use ; Section Editor</subject><ispartof>Current oncology reports, 2013-08, Vol.15 (4), p.424-432</ispartof><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-b8ecf71f3cba99c2c417e11ba3f6e896f5824b65f146906c2bbfd373c9736423</citedby><cites>FETCH-LOGICAL-c372t-b8ecf71f3cba99c2c417e11ba3f6e896f5824b65f146906c2bbfd373c9736423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11912-013-0330-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11912-013-0330-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23780822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fakhrejahani, Farhad</creatorcontrib><creatorcontrib>Hashemi Sadraei, Nooshin</creatorcontrib><creatorcontrib>Mekhail, Tarek</creatorcontrib><title>The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>Concurrent chemotherapy and radiation therapy remains the standard-of-care treatment in patients with unresectable stage III non-small-cell lung cancer. Most regimens include low doses of radiosensitizing agents. Because of concern for the presence of micrometastatic disease and the high rate of systemic failure, many trials have addressed the role of additional consolidation chemotherapy. Only a few of these studies have been performed in a randomized setting on a large number of patients, and the rest are smaller phase I and phase II trials that explore the safety and efficacy of different chemotherapy regimens. More recently, targeted agents have also been evaluated in such regimens, although molecular and histologic markers have not been fully incorporated in these studies. In this review, we discuss these trials and compare the different sequences and regimens of systemic doses of chemotherapy when delivered in addition to concurrent chemotherapy and radiation therapy.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Clinical Trials as Topic</subject><subject>Consolidation Chemotherapy - methods</subject><subject>Drug Substitution</subject><subject>Humans</subject><subject>Lung Cancer (T Mekhail</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm, Residual - drug therapy</subject><subject>Oncology</subject><subject>Radiation-Sensitizing Agents - therapeutic use</subject><subject>Section Editor</subject><issn>1523-3790</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kE1LxDAQhoMorl8_wIsUvHipZpJukh6l-MmioOs5pOlEK91Ek67gv7dlVxHBUwbyvO8MDyGHQE-BUnmWAEpgOQWeU85prjbIDkx5kQsmys1xZjznsqQTspvSK6WMUkW3yYRxqahibIfczl8wewgdZsFlVfApdG1j-jb4bB7R9Av0fdb6bBas6brP7Lz5MN5ikz35iAltb-ohe_dYzap9suVMl_Bg_e6R-eXFvLrOZ_dXN9X5LLdcsj6vFVonwXFbm7K0zBYgEaA23AlUpXBTxYpaTB0UoqTCsrp2DZfclpKLgvE9crKqfYvhfYmp14s2Wew64zEsk4YCQHCYihE9_oO-hmX0w3EahKRMAUg1ULCibAwpRXT6LbYLEz81UD161ivPevCsR896zBytm5f1ApufxLfYAWArIA1f_hnjr9X_tn4B5OmF8w</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Fakhrejahani, Farhad</creator><creator>Hashemi Sadraei, Nooshin</creator><creator>Mekhail, Tarek</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20130801</creationdate><title>The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC</title><author>Fakhrejahani, Farhad ; Hashemi Sadraei, Nooshin ; Mekhail, Tarek</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-b8ecf71f3cba99c2c417e11ba3f6e896f5824b65f146906c2bbfd373c9736423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Clinical Trials as Topic</topic><topic>Consolidation Chemotherapy - methods</topic><topic>Drug Substitution</topic><topic>Humans</topic><topic>Lung Cancer (T Mekhail</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm, Residual - drug therapy</topic><topic>Oncology</topic><topic>Radiation-Sensitizing Agents - therapeutic use</topic><topic>Section Editor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fakhrejahani, Farhad</creatorcontrib><creatorcontrib>Hashemi Sadraei, Nooshin</creatorcontrib><creatorcontrib>Mekhail, Tarek</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fakhrejahani, Farhad</au><au>Hashemi Sadraei, Nooshin</au><au>Mekhail, Tarek</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>15</volume><issue>4</issue><spage>424</spage><epage>432</epage><pages>424-432</pages><issn>1523-3790</issn><eissn>1534-6269</eissn><abstract>Concurrent chemotherapy and radiation therapy remains the standard-of-care treatment in patients with unresectable stage III non-small-cell lung cancer. Most regimens include low doses of radiosensitizing agents. Because of concern for the presence of micrometastatic disease and the high rate of systemic failure, many trials have addressed the role of additional consolidation chemotherapy. Only a few of these studies have been performed in a randomized setting on a large number of patients, and the rest are smaller phase I and phase II trials that explore the safety and efficacy of different chemotherapy regimens. More recently, targeted agents have also been evaluated in such regimens, although molecular and histologic markers have not been fully incorporated in these studies. In this review, we discuss these trials and compare the different sequences and regimens of systemic doses of chemotherapy when delivered in addition to concurrent chemotherapy and radiation therapy.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23780822</pmid><doi>10.1007/s11912-013-0330-8</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2013-08, Vol.15 (4), p.424-432 |
| issn | 1523-3790 1534-6269 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1411631562 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Clinical Trials as Topic Consolidation Chemotherapy - methods Drug Substitution Humans Lung Cancer (T Mekhail Lung Neoplasms - drug therapy Medicine Medicine & Public Health Neoplasm, Residual - drug therapy Oncology Radiation-Sensitizing Agents - therapeutic use Section Editor |
| title | The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A32%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20Consolidation%20Treatment%20in%20Locally%20Advanced%20Unresectable%20NSCLC&rft.jtitle=Current%20oncology%20reports&rft.au=Fakhrejahani,%20Farhad&rft.date=2013-08-01&rft.volume=15&rft.issue=4&rft.spage=424&rft.epage=432&rft.pages=424-432&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-013-0330-8&rft_dat=%3Cproquest_cross%3E3647107041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1670281178&rft_id=info:pmid/23780822&rfr_iscdi=true |